New obesity research reveals why GLP-1-based treatment may affect patients differently.

GLP-1-based treatment: Mayo Clinic study identifies an obesity subtype that may respond especially well

Obesity may be biologically different from one person to another, and new Mayo Clinic research suggests that a specific “hungry gut” subtype could respond particularly strongly to GLP-1-based treatment with tirzepatide.

The September 2026 study examined 483 adults with obesity and identified three biological subtypes, including a group characterised by lower production of appetite-regulating hormones, faster stomach emptying and greater hunger after meals.

About one in four participants belonged to this subtype, and they experienced an average 21.5% reduction in body weight after six months of tirzepatide treatment, compared with 11.7% among participants in the other groups.

The findings, published in Gastroenterology, provide evidence that obesity treatment could eventually become more personalised according to underlying biological mechanisms. The researchers caution that prospective studies are still required before this approach can become part of routine clinical practice.

The study also found that reduced hormone levels were associated with decreased intestinal hormone production rather than differences in the gut microbiome, providing a potentially important clue about the biology of this form of obesity.

Key Takeaways

Obesity consists of biologically distinct subtypes rather than a single uniform disease.
A “hungry gut” subtype was associated with lower appetite-regulating hormone production and faster stomach emptying.
This group lost an average 21.5% of body weight after six months of tirzepatide treatment.
Participants in other biological groups lost an average 11.7% over the same period.
Prospective research is needed before biological subtyping guides routine obesity treatment.

Obesity and the emerging science of GLP-1-based treatment

Obesity has traditionally been discussed in terms of body mass index, body weight, diet, physical activity and associated medical conditions. Those measurements remain clinically important, but modern obesity research increasingly recognises that excess body fat can arise and persist through different biological pathways.

The new Mayo Clinic study adds to that understanding by examining whether a person’s underlying physiology can help explain why the same anti-obesity medication produces substantially different results between patients.

The study focuses on GLP-1-based medications, particularly tirzepatide, and asks a clinically important question: why do some people experience substantial weight loss while others experience considerably more modest results from medications that act on appetite and metabolic regulation?

The answer proposed by the researchers is not that one medication works universally better than another. Instead, the findings suggest that the biological subtype of obesity may influence how strongly an individual responds to treatment. That distinction is important because it moves obesity research towards precision medicine, in which treatment selection is informed by disease biology rather than relying exclusively on broad characteristics such as body weight or BMI.

The Mayo Clinic researchers studied 483 adults with obesity and identified three different biological types of the disease. Approximately one in four participants had lower levels of GLP-1 and other hormones involved in signalling fullness after eating. This group also displayed physiological characteristics associated with what researchers describe as the “hungry gut” obesity phenotype.

Hers for Women’s Health

Hers is a one-stop shop for women’s health and personal care providing medical grade solutions for skin care, birth control, and sexual health. Everything is prescribed online and shipped directly to your door.

What is GLP-1 and why does it matter?

GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone involved in the regulation of appetite, food intake and blood glucose. It is produced in the intestine and participates in communication between the digestive system and the brain. Its physiological effects include promoting feelings of satiety after eating and influencing glucose regulation.

The development of medicines that reproduce or enhance the effects of gastrointestinal hormones has transformed the treatment of obesity and type 2 diabetes. Tirzepatide is particularly relevant to the Mayo Clinic research because it acts on two hormonal pathways involved in appetite and metabolic regulation.

The Mayo Clinic describes tirzepatide in the study as a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation. The drug therefore provides a useful intervention for investigating whether people with particular physiological characteristics respond differently to hormone-based treatment.

The significance of the new study lies in the possibility that differences in endogenous hormone biology may help explain differences in therapeutic response. Rather than assuming that all obesity operates through the same physiological mechanism, researchers are examining whether specific mechanisms can be identified and matched to particular treatments.

The “hungry gut” obesity phenotype

The term “hungry gut” refers to a proposed obesity phenotype involving an abnormal duration of fullness after eating. According to the Mayo Clinic study, people with this phenotype may consume normal-sized portions but experience hunger again relatively quickly, potentially leading to more frequent snacking between meals.

This is physiologically different from simply assuming that a person is consuming excessively large meals. The timing and persistence of appetite may be important components of the disease mechanism.

The study identified participants who produced lower levels of natural appetite-regulating hormones, experienced faster stomach emptying and reported greater hunger after meals. These characteristics were associated with the hungry-gut phenotype described by the researchers.

Gastric emptying is relevant because the rate at which food leaves the stomach contributes to gastrointestinal signalling. Digestion is not an isolated process occurring independently of the nervous and endocrine systems. The gastrointestinal tract continuously communicates with the brain and other organs through hormonal, neural and metabolic pathways.

The Mayo Clinic findings therefore place stomach emptying, intestinal hormone production and appetite regulation within a common physiological framework. They also provide a possible explanation for why individuals with apparently similar obesity can experience very different levels of hunger and different responses to treatment.

Hers The Shampooand Conditioner

Our signature shampoo to help control shedding is now packaged with our rich conditioner to make sure that all that hair you keep is luscious AF. More hair? ✔ Softer hair? ✔✔. Ah, the simple things.

Why tirzepatide produced different results between biological groups

The most striking finding in the study was the difference in weight loss between the biological subtypes.

Participants identified as having the low-hormone, hungry-gut phenotype lost an average of 21.5% of their body weight after six months of tirzepatide treatment. Participants belonging to the other biological groups lost an average of 11.7% during the same period.

The difference is clinically significant because it suggests that treatment response may be related to the biological mechanism driving obesity in an individual patient.

It is important, however, to interpret these figures within the boundaries of the study. The results do not establish that every person with this phenotype will lose 21.5% of body weight, nor do they demonstrate that biological classification can currently be used to select medication in routine clinical care. The Mayo Clinic authors explicitly state that prospective studies are needed before the approach can be incorporated into standard clinical practice.

The study therefore represents evidence for a potential treatment-response association rather than a validated clinical test for prescribing decisions.

From one-size-fits-all obesity treatment to precision medicine

Senior author Andres Acosta, MD, PhD, a gastroenterologist and obesity researcher at Mayo Clinic in Minnesota, describes the significance of the findings in the study:

“Obesity is a complex disease driven by different biological mechanisms,” says senior author Andres Acosta, MD, PhD, a gastroenterologist and obesity researcher at Mayo Clinic in Minnesota. “Our findings suggest we can begin identifying which patients are most likely to respond to specific therapies rather than treating obesity as a single disease.”

That statement captures the central scientific implication of the research. Obesity is increasingly understood as a chronic disease involving interactions among appetite regulation, energy balance, gastrointestinal physiology, endocrine signalling, genetics, metabolism and environmental factors.

A precision-medicine model would seek to identify which mechanism is particularly relevant in a given patient and then select treatment accordingly. Such an approach could potentially reduce ineffective treatment cycles and improve the process of finding an appropriate therapy.

The concept remains under investigation. Before biological subtypes can be translated into routine clinical algorithms, researchers need to determine whether the classification can be reproduced reliably, whether it predicts treatment response prospectively and whether using it to guide treatment improves patient outcomes.

Wegovy® Pen

An FDA-approved GLP-1 injection
Clinically proven to help people lose 35 lbs in one year, on average1
Range of dosages from 0.25mg–7.2mg

The intestine, not necessarily the microbiome

Another important finding concerns the biological origin of the reduced hormone levels.

The researchers found that lower levels of appetite-regulating hormones were associated with decreased hormone production in the intestine rather than differences in the gut microbiome. This distinction matters because the gut microbiome has received considerable attention in obesity research.

Understanding the distinction may help researchers investigate obesity at a more precise physiological level. Instead of searching for a single explanation for obesity, researchers can examine separate biological pathways and determine how they contribute to appetite, satiety, gastric emptying and response to medication.

What the findings mean for people living with obesity

The study’s findings could eventually have implications for how obesity is assessed and treated, although they do not currently establish a new standard of care.

Obesity is associated with an increased risk of several serious chronic conditions, including diabetes, cardiovascular disease and certain cancers. The Mayo Clinic research notes that identifying an effective therapy earlier could potentially improve long-term health outcomes.

The potential benefit of biological classification would therefore extend beyond achieving a particular number on a weighing scale. Effective obesity treatment can involve improvements in metabolic health and reductions in disease risk, alongside changes in body weight.

The research also reinforces the importance of recognising obesity as a chronic disease with biological mechanisms rather than reducing it to a matter of personal behaviour. Appetite, satiety, hormone signalling and gastrointestinal physiology can all influence eating behaviour and energy balance.

Wegovy® Pill

Wegovy^® is an FDA-approved semaglutide pill for weight loss
Clinically proven to help people lose 32 lbs in one year, on average^*

What happens next in GLP-1-based treatment research?

The next stage of research will be determining whether the biological characteristics identified by the Mayo Clinic investigators can reliably predict treatment response before therapy begins.

That requires prospective studies in which patients are classified according to biological characteristics and then followed systematically through treatment. Researchers will need to establish whether the phenotype remains stable, whether the same relationship appears in larger and more diverse populations, and whether biological classification can be measured efficiently enough for clinical use.

The study’s authors themselves caution that additional prospective research is necessary. That qualification is particularly important because a promising association in an exploratory research setting is not equivalent to a clinically validated treatment-selection tool.

The work nevertheless represents an important development in the scientific understanding of obesity. It suggests that the question is evolving from whether a particular anti-obesity medication works on average to why its effects vary between individuals.

A more precise understanding of obesity

The Mayo Clinic study adds another layer to the rapidly developing science of obesity. Its central finding is that a biologically identifiable group of people with obesity, characterised by reduced intestinal production of appetite-regulating hormones, faster gastric emptying and greater post-meal hunger, experienced substantially greater average weight loss with tirzepatide than participants in other identified biological groups.

The findings do not mean that every patient should undergo biological subtype testing before receiving treatment, because the researchers have not established such an approach as routine clinical practice. They do demonstrate why treatment response cannot necessarily be understood from body weight alone.

GLP-1-based treatment has opened a new chapter in obesity medicine by targeting biological pathways involved in appetite and metabolic regulation. The Mayo Clinic research suggests that the next chapter may involve determining which patients are biologically predisposed to respond particularly strongly to individual therapies.

That would represent a significant shift in obesity medicine, from treating obesity primarily according to outward measurements towards understanding the physiological mechanisms operating inside each patient.

For now, the research remains an important scientific finding rather than a new clinical prescribing rule. Its significance lies in demonstrating that the biology of obesity may provide valuable information about treatment response, while also establishing the need for further prospective evidence before personalised biological classification becomes part of everyday clinical care.

For financial disclosures and other details, please see the paper.